Compounds

A method for the treatment of dyslipidemia comprising administering to a human or animal patient in need thereof a pharmaceutically effective amount of a compound of formula (I)

• wherein R1 and R2 are the same or different and are chosen from a hydrogen atom, an alkyl group, a halogen atom, a hydroxy group, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group;
• and
• X represents a carboxylic acid group or a carboxylate group, or any pharmaceutically acceptable salt thereof;
• with the provisos that:
• the compound of formula (I) not (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA), alpha-methyl DHA, alpha-methyl DHA methyl ester, alpha-methyl DHA ethyl ester, or alpha-hydroxy DHA ethyl ester, and R1 and R2 are not simultaneously a hydrogen atom.

A method for reducing insulin, blood glucose, and/or serum triglyceride levels by administering to a human or animal patient in need thereof a pharmaceutically effective amount of a compound of formula (I)

• wherein R1 and R2 are the same or different and are chosen from a hydrogen atom, an alkyl group, a halogen atom, a hydroxy group, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group;
• and
• X represents a carboxylic acid group or a carboxylate group, or any pharmaceutically acceptable salt thereof;
• with the provisos that:
• the compound of formula (I) is not (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA), alpha-methyl DHA, alpha-methyl DHA methyl ester, alpha-methyl DHA ethyl ester, or alpha-hydroxy DHA ethyl ester, and R1 and R2 are not simultaneously a hydrogen atom.

A method for reducing body weight by administering to a human or animal patient in need thereof a pharmaceutically effective amount of a compound of formula (I)

• wherein R1 and R2 are the same or different and are chosen from a hydrogen atom, an alkyl group, a halogen atom, a hydroxy group, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group;
• and
• X represents a carboxylic acid group or a carboxylate group, or any pharmaceutically acceptable salt thereof;
• with the provisos that:
• the compound of formula (I) is not (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA), alpha-methyl DHA, alpha-methyl DHA methyl ester, alpha-methyl DHA ethyl ester, or alpha-hydroxy DHA ethyl ester, and R1 and R2 are not simultaneously a hydrogen atom.

A method for activating and/or mediating at least one human peroxisome proliferator-activated receptor (PPAR) isoforms by administering to a human or animal patient in need thereof a pharmaceutically effective amount of a compound of formula (I)

• wherein R1 and R2 are the same or different and are chosen from a hydrogen atom, an alkyl group, a hydroxy group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group;
• and
• X represents a carboxylic acid group or a carboxylate group, or any pharmaceutically acceptable salt thereof;
• with the provisos that:
• the compound of formula (I) is not (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA), alpha-methyl DHA, alpha-methyl DHA methyl ester, alpha-methyl DHA ethyl ester, or alpha-hydroxy DHA ethyl ester, and R1 and R2 are not simultaneously a hydrogen atom.

A pharmaceutical composition comprising a compound of formula (I):

• wherein R1 and R2 are the same or different and are chosen from a hydrogen atom, an alkyl group, a halogen atom an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group;
• and
• X represents a carboxylic acid group or a carboxylate group,
• or any pharmaceutically acceptable salt thereof;
• with the provisos that:
• the compound of formula (I) is not (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA), alpha-methyl DHA, alpha-methyl DHA methyl ester, alpha-methyl DHA ethyl ester, or alpha-hydroxy DHA ethyl ester, and R1 and R2 are not simultaneously a hydrogen atom.

A pharmaceutical composition comprising a compound of formula (I):

• wherein R1 and R2 are the same or different and are chosen from a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, and acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, and alkylthio group, an alkoxycarbonyl group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, or an alkylamino group;
• and
• X represents a carboxylic acid group,
• or any pharmaceutically acceptable salt thereof;
• with the provisos that:
• the compound of formula (I) is not (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA), alpha-methyl DHA, alpha-methyl DHA methyl ester, alpha-methyl DHA ethyl ester or alpha-hydroxy DHA ethyl ester, and R1 and R2 are not simultaneously a hydrogen atom.

A pharmaceutical composition comprising a compound of formula (I):

• wherein R1 and R2 are the same or different and are chosen from a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, and acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, andalkylthio group, an alkoxycarbonyl group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, or an alkylamino group;
• and
• X represents a carboxylic acid group, wherein the carboxylic acid is present as its diglyceride derivative;
• with the provisos that:
• the compound of formula (I) is not (all-Z)-4,7,10,13,16,10,19-docosahexaenoic acid (DHA), alpha-methyl DHA, alpha-methyl DHA methyl ester, alpha-methyl DHA ethyl ester or alpha-hydroxy DHA ethyl ester, and R1 and R2 are not simultaneously a hydrogen atom.